Paolo Tarantino/X
Apr 19, 2025, 08:10
Paolo Tarantino: Trastuzumab Emtansine vs. Second Topoisomerase I-Based ADC After Trastuzumab Deruxtecan
Paolo Tarantino, Research Fellow presso Dana-Farber Cancer Institute, posted on X:
“In our retrospective Flatiron data presented at SABCS24, Trastuzumab Emtansine did seem to outperform a second topo1 ADC after progression on prior T-DXd.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 8, 2025, 17:21
Aug 8, 2025, 17:21
Aug 8, 2025, 16:46
Aug 8, 2025, 16:41
Aug 8, 2025, 16:31
Aug 8, 2025, 16:11
Aug 8, 2025, 15:57
Aug 8, 2025, 15:54